Data from a new study suggests that prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging is superior to 18F-fluciclovine PET for detecting biochemical recurrence in men with prostate cancer. However, whether one of these radiotracers improves patient survival over the other is unknown and further research is needed to determine which has the greater effect.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Simmons, M. N., Stephenson, A. J. & Klein, E. A. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur. Urol. 51, 1175–1184 (2007).
Lindenberg, M. L. et al. Imaging locally advanced, recurrent, and metastatic prostate cancer: a review. JAMA Oncol. 3, 1415–1422 (2017).
Mena, E., Lindenberg, L. M. & Choyke, P. L. New targets for PET molecular imaging of prostate cancer. Semin. Nucl. Med. 49, 326–336 (2019).
US Food & Drug Administration. FDA approves new diagnostic imaging agent to detect recurrent prostate cancer. FDA https://www.fda.gov/news-events/press-announcements/fda-approves-new-diagnostic-imaging-agent-detect-recurrent-prostate-cancer (2016).
Calais, J. et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 20, 1286–1294 (2019).
Savir-Baruch, B. et al. ACR-ACNM practice parameter for the performance of fluorine-18 fluciclovine-PET/CT for recurrent prostate cancer. Clin. Nucl. Med. 43, 909–917 (2018).
Tan N. et al. Imaging of prostate specific membrane antigen targeted radiotracers for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis. J. Urol. 202, 231–240 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Turkbey, B., Choyke, P.L. 18F-fluciclovine PET or PSMA PET for prostate cancer imaging?. Nat Rev Urol 17, 9–10 (2020). https://doi.org/10.1038/s41585-019-0255-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-019-0255-6